F Fuzkk Atlas of the USA
#208Extended selection 101–500

Akebia Therapeutics

Massachusetts / New England

Finished dosage forms and small molecules

Manufacturing profile

Finished dosage forms and small molecules

Biopharma hub: Massachusetts / New England

Selection basis

The company is placed in positions 101–500 as a manufacturer, biotech, generics, advanced-therapy company or CDMO with practical relevance to the FUZKK utility catalog.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Representative manufacturing and QC chain

  1. 1Raw-material receipt and identification
  2. 2Dispensing, blending and granulation
  3. 3Tableting, encapsulation or solution preparation
  4. 4Packaging and labelling
  5. 5HPLC, GC, KF, ICP/AAS, dissolution and stability QC

Relevant FUZKK packages

United States: national essential medicines QC packageChina: national essential medicines QC packageGlobal API & Biosimilars QC SuiteLumex QC SuiteLabEx QC Suite

Product/API utilities

Assay & Impurities Result Reviewer

Lumex — instrumental QC

System Suitability Parameters Checker

LabEx — laboratory QC

Assay & Impurity HPLC Quality CheckerResidual Solvents GC Quality CheckerWater Content KF Quality CheckerElemental Impurities ICP Quality CheckerContent Uniformity Quality CheckerDissolution Apparatus 1 & 2 Quality CheckerStability Condition Monitoring Quality Checker

Medical Devices — equipment and software lifecycle

Process Validation CheckerData Integrity Security CheckerSupplier Evaluation CheckerCalibration Status CheckerChange Control Impact CheckerRequirement Traceability Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Methodology